MEDP
Medpace Holdings, Inc.Company with tickers: MEDP
CIK
1668397
CUSIP
58506Q109
Shares Outstanding
28,559,689
Website
https://www.medpace.com
13F Activity (30d)
47 filings
33 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $7,300,000 | USD | 2026-03-31 | 10-Q | 2026-04-23 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | — | ||||
| Operating Income | $141,503,000 | USD | 2026-03-31 | 10-Q | 2026-04-23 |
| Net Income | $123,870,000 | USD | 2026-03-31 | 10-Q | 2026-04-23 |
| EPS (Basic) | $4.35 | USD/shares | 2026-03-31 | 10-Q | 2026-04-23 |
| EPS (Diluted) | $4.28 | USD/shares | 2026-03-31 | 10-Q | 2026-04-23 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|
| Oncology | $362,846,000 | $467,796,000 | $587,097,000 | $651,237,000 | $747,585,000 |
| Metabolic | $159,900,000 | $244,682,000 | $376,842,000 | $457,542,000 | $744,957,000 |
| Other | $267,415,000 | $296,914,000 | $404,844,000 | $431,384,000 | $408,548,000 |
| Central Nervous System | $121,548,000 | $157,939,000 | $160,057,000 | $181,977,000 | $254,838,000 |
| Cardiology | $119,692,000 | $174,634,000 | $193,690,000 | $230,454,000 | $239,371,000 |
| Antiviral And Anti Infective | $110,976,000 | $118,031,000 | $163,312,000 | $156,460,000 | $134,935,000 |
| Revenue Net | $1,142,377,000 | $1,459,996,000 | $1,885,842,000 | — | — |